logo

For the Inventor, By the Inventor

Mainz, Germany

Ganymed Pharmaceuticals Ag

Calculating rank
USPTO Granted Patents = 51

% Expired Patents = 31.4



Forward Citations = 443

Loading Chart...
Loading Chart...

53 inventors (with patents filed for the assignee):

goldMedal Ugur Sahin (49 out of 196 patents)

silverMedal Michael Koslowski (33 out of 53 patents)

bronzeMedal Özlem Türeci (27 out of 53 patents)

4.  Ozlem Tureci (21 out of 54 patents)

5.  Dirk Usener (11 out of 19 patents)

6.  Rita Mitnacht-Kraus (7 out of 17 patents)

7.  Stefan Woll (7 out of 16 patents)

8.  Korden Walter (7 out of 18 patents)

9.  Gerd Helftenbein (7 out of 15 patents)

10.  Maria Kreuzberg (6 out of 15 patents)

11.  Harald-Gerhard Geppert (6 out of 10 patents)

12.  Volker Schlüter (6 out of 13 patents)

13.  Stefan Fritz (5 out of 9 patents)

14.  Gunda Brandenburg (5 out of 9 patents)

15.  Bernd Hubner (4 out of 8 patents)


Core Competencies:
Claudin-6
Monoclonal Antibodies
Cancer Diagnosis
Tumor Antigens
Combination Therapy
Claudin-18
Immunotherapy
Genetic Products
Targeted Therapy
In Vivo Treatment
Tumor-Associated Antigens
Epitopes

51 patents:

1. 12760115 - ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS (2026-10-13),
2. 11345731 - Claudin-6-specific immunoreceptors and t cell epitopes (2022-05-31),
3. 10414824 - Genetic products differentially expressed in tumors and the use thereof (2019-09-17),
4. 10370423 - Claudin-6-specific immunoreceptors and T cell epitopes (2019-08-06),
5. 10233253 - Antibodies for treatment of cancer expressing claudin 6 (2019-03-19),
6. 10125196 - Monoclonal antibodies for treatment of cancer (2018-11-13),
7. 10093736 - Agents for treatment of claudin expressing cancer diseases (2018-10-09),
8. 10053512 - Antibodies against claudin 18.2 useful in cancer diagnosis (2018-08-21),
9. 10036753 - Identification of surface-associated antigens for tumor diagnosis and therapy (2018-07-31),
10. 10022444 - Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer (2018-07-17),
11. 9932401 - Antibodies specific for claudin 6 (CLDN6) (2018-04-03),
12. 9919036 - Identification of tumor-associated antigens for diagnosis and therapy (2018-03-20),
13. 9902778 - Cancer therapy using CLDN6 target-directed antibodies in vivo (2018-02-27),
14. 9809815 - Methods and compositions for diagnosis and treatment of cancer (2017-11-07),
15. 9775785 - Antibody to genetic products differentially expressed in tumors and the use thereof (2017-10-03),
Company Overview
Ganymed Pharmaceuticals AG, based in Mainz, Germany, is a biopharmaceutical company specializing in cancer immunotherapy. The organization focuses on the development of innovative therapeutic solutions targeting tumor antigens, particularly Claudin-6 and Claudin-18. Ganymed's expertise encompasses monoclonal antibodies and combination therapies aimed at enhancing cancer diagnosis and treatment. Through its advanced research in genetic products and immunotherapy, Ganymed is committed to improving outcomes for patients with various forms of cancer.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

51 Patents

#7 in Mainz

#1,038 in Germany

#13,798 in the World

Mainz, DE
Mainz, Germany

Ganymed Pharmaceuticals Ag

Forward Citations = 443

53 inventors:

goldMedal Ugur Sahin (49 out of 196 patents)

silverMedal Michael Koslowski (33 out of 53 patents)

bronzeMedal Özlem Türeci (27 out of 53 patents)

4.  Ozlem Tureci (21 out of 54 patents)

5.  Dirk Usener (11 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ganymed Pharmaceuticals Ag. Retrieved from https://idiyas.com/company/ganymed-pharmaceuticals-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…